Drugs / Furazolidone

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) FUROXONE 1958-01-20 fda.gov

Trials 24 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT06823791 Aug 2022 → Jul 2024 Helicobacter pylori infectious disease Liaocheng People's Hospital Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT01730352 Oct 2008 → May 2011 Helicobacter pylori infectious disease, autoimmune thrombocytopenic purpura Federal University of São Paulo Completed No outcome recorded
Phase 414 trials
Phase 4 NCT06168214 Sep 2023 → Nov 2024 overdue Xijing Hospital of Digestive Diseases Recruiting No outcome recorded
Phase 4 NCT05718609 Mar 2023 → Mar 2024 Helicobacter pylori infectious disease Second Affiliated Hospital, School of Medicine, Zhejiang University Unknown No outcome recorded
Phase 4 NCT05345210 Apr 2022 → Feb 2023 Helicobacter pylori infectious disease Xijing Hospital of Digestive Diseases Unknown No outcome recorded
Phase 4 NCT05135182 Nov 2021 → Oct 2022 Helicobacter pylori infectious disease Shandong University Unknown No outcome recorded
Phase 4 NCT04264663 Nov 2019 → Oct 2022 Helicobacter pylori infectious disease Shandong University Unknown No outcome recorded
Phase 4 NCT03616405 Apr → Nov 2019 Helicobacter pylori infectious disease Shandong University Unknown No outcome recorded
Phase 4 NCT03726099 Mar 2019 → Apr 2020 Helicobacter pylori infectious disease Shandong University Unknown No outcome recorded
Phase 4 NCT03565484 Jan 2019 → May 2020 Helicobacter pylori infectious disease Shandong University Unknown No outcome recorded
Phase 4 NCT03716622 Jul 2018 → Aug 2019 Helicobacter pylori infectious disease Shandong University Completed No outcome recorded
Phase 4 NCT03571230 Jul 2018 → Dec 2019 Helicobacter pylori infectious disease Shandong University Unknown No outcome recorded
Phase not applicable8 trials
NCT06340334 Mar 2024 → Sep 2025 Helicobacter pylori infectious disease Nanjing First Hospital, Nanjing Medical University Completed No outcome recorded
NCT05549115 Sep 2022 → Feb 2024 Helicobacter pylori infectious disease Liaocheng People's Hospital Unknown No outcome recorded
NCT05133193 Nov 2021 → Jun 2022 Helicobacter pylori infectious disease Shandong University Unknown No outcome recorded
NCT05126121 Nov 2021 → Jun 2022 Helicobacter pylori infectious disease Xiuli Zuo Unknown No outcome recorded
NCT04991584 Aug 2021 → Jun 2022 Helicobacter pylori infectious disease Shandong University Unknown No outcome recorded
NCT05097846 Jun 2021 → Jun 2022 Helicobacter pylori infectious disease wang xiaoyan Unknown No outcome recorded
NCT02689583 Mar 2016 → Mar 2017 gastric ulcer, gastritis First Affiliated Hospital of Zhejiang University Unknown No outcome recorded
NCT00520949 Oct 2006 → Jun 2008 Aga Khan University Completed No outcome recorded
Also used as a comparator or background therapy in 17 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT06777732 Background Mar → Sep 2025 overdue Helicobacter pylori infectious disease Nanjing First Hospital, Nanjing Medical University Not yet recruiting No outcome recorded
Phase 11 trial
Phase 1 NCT05586464 Comparator Nov 2022 → Sep 2024 Helicobacter pylori infectious disease Liaocheng People's Hospital Unknown No outcome recorded
Phase 21 trial
Phase 2 NCT01805934 Comparator May → Dec 2012 Shanghai Jiao Tong University School of Medicine Completed No outcome recorded
Phase 31 trial
Phase 3 NCT06760065 Comparator Jan 2025 → Dec 2027 expected Helicobacter pylori infectious disease Sixth Affiliated Hospital, Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 410 trials
Phase 4 NCT07139366 Background Oct 2025 → Sep 2026 expected Helicobacter pylori infectious disease, dyspepsia, gastric cancer, gastritis +1 Yongquan Shi Recruiting No outcome recorded
Phase 4 NCT06168084 Comparator Jun 2023 → May 2024 stomach disorder Yongquan Shi Completed No outcome recorded
Phase 4 NCT04907747 Background May 2021 → Apr 2022 Helicobacter pylori infectious disease Second Affiliated Hospital, School of Medicine, Zhejiang University Unknown No outcome recorded
Phase 4 NCT04660123 Background Dec 2020 → Dec 2021 Helicobacter pylori infectious disease, gastric cancer Xijing Hospital of Digestive Diseases Completed No outcome recorded
Phase 4 NCT04678492 Comparator Dec 2020 → Dec 2021 Helicobacter pylori infectious disease, dyspepsia, gastric cancer, gastritis +1 Xijing Hospital of Digestive Diseases Completed No outcome recorded
Phase not applicable3 trials
NCT05191875 Background Dec 2021 → Apr 2022 Helicobacter pylori infectious disease The Third Xiangya Hospital of Central South University Completed No outcome recorded
NCT05410223 Background Apr 2021 → Dec 2022 Helicobacter pylori infectious disease The Third Xiangya Hospital of Central South University Unknown No outcome recorded
NCT05176821 Comparator Jan 2021 → Dec 2022 Helicobacter pylori infectious disease Shanghai Zhongshan Hospital Unknown No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 42 sources stand behind the page.

FieldValueCited text
Known as furazolidone “Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to...” NCT01730352
40

“Dose of two sensitive antibiotics are listed as follows : amoxicillin 1000mg bid, clarithromycin 500mg bid, tinidazole 500mg tid, levofloxacin 500mg qd, furazolidone 100mg bid,...” NCT03565484

“Multi-drug resistant strains: Esomeprazole 20 mg, Bismuth Potassium Citrate 220 mg, Amoxicillin 1 g, and either Furazolidone 0.1 g (twice daily) or Tetracycline 500 mg (four...” NCT06760065

“esomeprazole (20 mg, twice daily), furazolidone (100 mg, twice daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily) for 14 days” NCT05549115

“Group B subjects received oral Tegoprazan 50 mg, bid + amoxicillin 1000 mg, bid + furazolidone 100 mg, bid + colloidal pectin bismuth 300 mg, bid.” NCT06340334

“priority antibiotic selection was as follow: Amoxicillin \> Clarithromycin \> Levofloxacin \>Tetracycline \> Furazolidone \> Metronidazole.” NCT02689583

“Few published paper evaluated the efficacy of 14-day furazolidone containing concomitant therapy in the third line treatment.” NCT05133193

“including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).” NCT01805934

“Scheme 3 Amoxicillin 1000 mg, 2 times/d; Furazolidone 100mg, 2 times/d.” NCT04660123

furazolidone (Tablets100mg/tablet,100mg bid)” NCT05586464

“Furoxone (furazolidone)” NCT00520949

furazolidone tablets” NCT04034641

“Drug: FurazolidoneNCT07139366

NCT03616405

NCT05191875

NCT03609892

NCT02894268

NCT06777732

NCT03139253

NCT06168084

NCT05135182

NCT03716622

NCT05345210

NCT03342456

NCT05126121

NCT05176821

NCT01668927

NCT03726099

NCT04264663

NCT06823791

NCT03658746

NCT04678492

NCT03658733

NCT05718609

NCT05410223

NCT04907747

NCT05097846

NCT03571230

NCT04991584

NCT06168214

NCT02988089

Known as Furall ChEMBL registry synonym — accepted as the source's own label CHEMBL1103
Known as Furazolidona ChEMBL registry synonym — accepted as the source's own label CHEMBL1103
Known as Furoxone ClinicalTrials.gov intervention name — accepted as the source's own label NCT00520949
Known as Liteling “furazolidone (Liteling) 100mg po bid for 14d” NCT03716622
Known as NSC-6469 ChEMBL registry synonym — accepted as the source's own label CHEMBL1103
Modality Small molecule CHEMBL1103
Route Oral “Children able to swallow tablets or capsules, above 30kg: clarithromycin 500mg, amoxicillin 500mg, furazolidone 200mg, and/ or doxycycline 100mg, all 2 times per day, for 14 days.” NCT01730352